Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises ITAB on its acquisition of HMY
Mandate

Vinge advises ITAB on its acquisition of HMY

September 26, 2024

ITAB Shop Concept AB (publ) has entered into an agreement intended to lead to the acquisition of Financière HMY for EUR 320 million. The transaction is intended to be financed by a new long term credit facility of EUR 255 million, and a directed new share issue of approx. SEK 867 million which was carried out through an accelerated book-built offering.

The Vinge team includes Erik Sjöman, Christian Lindhé, Jesper Ottergren, Henrik Borna, Henrik Ossborn, Martin Madsen Svanberg, Fredrik Christiansson and Johan Åhman.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026